Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will s ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

The FDA published a report highlighting a "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" as a potential signal of serious risk with Vyvgart Hytrulo (efgartigimod alfa ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

For the millions of Americans battling autoimmune disorders, new hope may be on the horizon in the form of reverse or inverse ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

In the announcement by the National Institute for Health and Care Excellence (NICE) it confirms that Zilucoplan (Zilbrysq) ...